NEW YORK, March 22, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Cemtrex, Inc. securities (NASDAQ:CETX) from October 26, 2016 through February 22, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Cemtrex investors under the federal securities laws.
To join the Cemtrex class action, go to http://www.rosenlegal.com/cases-1059.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Aron Govil’s role at Southern Steel & Construction Inc., which has been paying a notorious stock promoter, Small Cap Specialists, to promote Cemtrex’s stock; and (2) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. On February 22, 2017, Seeking Alpha published an article asserting that over $1 million has been paid to notorious stock promoters to promote Cemtrex, and Cemtrex’s founder, Defendant Aron Govil, is secretly paying promoters behind imploded frauds like Forcefield Energy and Code Rebel via an undisclosed entity. On this news, shares of Cemtrex fell $1.72 per share or over 33.5% from its previous closing price to close at $3.40 per share on February 22, 2017, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 25, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1059.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer
xAI Cash Burn Highlights the High Cost of Competing in Generative AI
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable”
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 



